ACHV Achieve Life Sciences Inc
Company Analysis
Latest News
🟢 Achieve Life Sciences is trading 6% up in pre-market today amid a possible biotech sentiment rebound
Achieve Life Sciences is trading at $8.50 (+5.99%), with no new company-specific announcement dated August 21, 2026 identified. - The latest official listing...
🔴 Achieve Life Sciences falls 5.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Achieve Life Sciences Hits 52-Week High, Advancing Smoking Cessation Drug
Achieve Life Sciences (NASDAQ:ACHV) reached a new 52-week high of $7.60 on Wednesday. The stock closed the session at $7.52. Investor confidence is growing in...
🟢 Achieve Life Sciences is trading 10.2% up today amid biotech-sector momentum
Achieve Life Sciences is trading 10.2% up at $8.29, with sector momentum the clearest explanation on August 19, 2026. - The stock is outperforming the broader...
🟢 Achieve Life Sciences rises 6.4% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Achieve Life Sciences launches $150 million at-the-market program for cytisinicline during third quarter 2026
Achieve Life Sciences entered into an at-the-market (ATM) equity offering agreement to sell up to $150.0 million in common stock. The company intends to...
🟢 Achieve Life Sciences is trading 5.68% up today after Morgan Stanley initiated Overweight coverage
Achieve Life Sciences is trading at $7.07 (+5.68%) after Morgan Stanley initiated coverage on August 13, 2026, with an Overweight rating and a $13.00 price...
Achieve Life Sciences second quarter cash hits $187M as fourth quarter NDA resubmission nears
Achieve Life Sciences reported a net loss of $74.8 million for the second quarter of 2026, a result heavily impacted by a $48.7 million non-cash warrant...
Achieve Life Sciences Reports Q2 Results, Shifts Manufacturing to United States
Achieve Life Sciences announced its second-quarter 2026 financial results on August 10, 2026. The clinical-stage pharmaceutical company is currently advancing...
🟢 Achieve Life Sciences is trading 5% up today in pre-market
Achieve Life Sciences is trading 5% up now at $6.88 in pre-market after rising from the August 6 close of $6.55; no clear catalyst was identified. - No clear...
🔴 Achieve Life Sciences is trading 5.9% down today ahead of its August 6 earnings report
Achieve Life Sciences is trading 5.9% down at $6.09 as investors appear to be repositioning ahead of the company's upcoming quarterly financial results. • The...
Achieve Life Sciences Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Achieve Life Sciences is projected to report a consensus EPS loss of $0.18 on zero revenue for Q2 2026, with the stock currently trading at $4.42 against an...
🔴 Achieve Life Sciences is trading 7.3% down today amid low-liquidity pre-market dynamics
Achieve Life Sciences is trading at $5.95 (7.3% down), reversing its mild gains from late July. • The move appears driven by typical low-liquidity pre-market...
🟢 Achieve Life Sciences is trading 5.4% up today on continued momentum and market sentiment
Achieve Life Sciences is trading at $6.43 (+5.41%) today, extending recent gains amid a broader risk-on market sentiment. • The stock continues to build on...
🟢 Achieve Life Sciences is trading 5.4% up today in a rebound following a selloff driven by an FDA Complete Response Letter
Achieve Life Sciences is trading 5.4% up today at $6.28, rebounding after a sharp decline triggered by an FDA Complete Response Letter (CRL) for cytisinicline...
🔴 Achieve Life Sciences is trading 5.3% down today following FDA CRL and financing pressure
Achieve Life Sciences is trading 5.3% down at $6.00, extending a decline triggered by an FDA Complete Response Letter (CRL) for cytisinicline and significant...
🔴 Achieve Life Sciences Is Trading 6.7% Down Today Amid Annual Stockholder Meeting and Share Increase Proposal
Achieve Life Sciences is trading 6.7% down at $5.97 today, following its 2026 Annual Meeting of Stockholders. During the meeting, stockholders voted on a...
🔴 ACHV is trading 5.5% down today on profit-taking after share authorization rally
ACHV is trading 5.5% down at $6.16 on profit-taking following a sharp rally driven by expanded share authorization. • Shareholders recently approved doubling...
🟢 ACHV is trading 6.2% up today after shareholders approve doubling authorized common shares
ACHV is trading at $6.85 (6.2% up) in pre-market after investors approved doubling the company's authorized common shares from 150 million to 300 million at...
Stockholders Approve Doubling of Authorized Common Stock to 300M Shares
Achieve Life Sciences announced that its stockholders have approved a proposal to amend the company's Certificate of Incorporation, doubling the number of...